EX-99.2

Please wait

Forward -looking statements Disclaime r This material has b een mad e availab le to you with the consent of Vera Therap eutics, Inc. ( we , us , our , or the Comp any ). State me nts in this p re se ntation that are not state me nts of historical fact are forward -looking state me nts within the me aning of the Private Se curitie s Litig ation Re form Act of 1995. Such forward -looking state me nts includ e , without limitation, TRUTAKNA 's ab ility to transform tre atme nt of autoimmune d ise ase ; the e xp e cte d timing of sBLA sub mission for TRUTAKNA; the p ote ntial for TRUTAKNA to offe r p re cision mod ulation of B ce lls and autoantib od ie s; the timing of and p ote ntial for the U.S. FDA to g rant full ap p roval of TRUTAKNA; the ab ility for TRUTAKNA to achieve results that reflect comp rehensive d isease mod ification in Ig AN; the estimated Ig AN ep id emiolog y in 2032; the p otential for TRUTAKNA to achieve the KDIGO Clinical Practice Guid e line s; the p ote ntial marke t op p ortunity in p ip e line autoimmune d ise ase s; the comme rcial op p ortunity of Ig AN and TRUTAKNA; and the Comp any's e xp e ctations re g ard ing the timing of clinical trial re sults for EXTEND and PIO NEER trials. Word s such as “anticip ate ,” “p lan,” “e xp e ct,” “will,” “may,” “p ote ntial,” “p roje cte d ,” “p romise ” and similar e xp re ssions are inte nd e d to id e ntify forward -looking state me nts, though not all forward -looking state me nts ne ce ssarily co ntain the se id e ntifying wo rd s. The se fo rward -looking statements are b ased on the b eliefs of the Comp any’s manag ement as well as assump tions mad e b y and information curre ntly availab le to the Comp any. Such state me nts re fle ct the curre nt vie ws of the Comp any with re sp e ct to future e ve nts and are sub je ct to known and unknown risks, includ ing b usine ss, re g ulatory, e conomic and comp e titive risks, unce rtaintie s, conting e ncie s and assump tions ab out the Comp any, includ ing , without limitation, risks re late d to the re g ulatory ap p roval p roce ss, the p ote ntial that re sults of e arlie r clinical trials may not b e ob taine d in late r clinical trials, risks and unce rtaintie s associated with the Comp any's b usiness in g eneral, the imp act of macroe conomic and g e op olitical e ve nts, and the othe r risks d e scrib e d in the Comp any's filing s with the U.S. Se curitie s and Exchang e Commission, includ ing those d e scrib e d und e r the cap tion Risk Factors in our most re ce nt Annual Re p ort on Form 10-K and Q uarte rly Re p ort on Form 10-Q . In lig ht of these risks and uncertainties, the events or circumstance s re fe rre d to in the fo rward -looking state me nts may not occur. The actual re sults may vary from the anticip ate d re sults and the variations may b e mate rial. The se forward -looking state me nts should not b e take n as fore casts or p romise s nor should the y b e take n as imp lying any ind ication, assurance or g uarante e that the assump tions on which such forward -looking statements have b een mad e are correct or exhaustive or, in the case of the assump tions, fully stated in this p re se ntation. You are cautione d not to p lace und ue reliance on these forward -looking statements, which sp eak only as of the d ate of this p resentation, and are b ased on manag e me nt's assump tions and e stimate s as of such d ate . The Comp any und e rtake s no ob lig ation to up d ate such state me nts to re fle ct e ve nts that occur or circumstance s that exist after the d ate on which they were mad e, excep t as req uired b y law. This p re se ntation d iscusse s p rod uct cand id ate s that are und e r clinical stud y and which have not ye t b e e n fully ap p rove d for marke ting b y the U.S. Food and Drug Ad ministration. No rep resentation is mad e as to the safety or effectiveness of these p rod uct cand id ates for the use for which such p roduct candidate s are be ing studie d to the extent it has not yet b een ap p roved . The trad emarks includ ed herein are the p rop erty of the owners thereof and are used for reference p urp oses only. Such use should not b e construe d as an e nd orse me nt of such p rod ucts. 2 © 2026 Vera Therapeutics, Inc. Corporate Presentation

• VERA (Nasd aq ) is a San Francisco-b ased b iotechnolog y comp any with world -class d evelop ment and commercialization lead ership • First comme rcial p rod uct: TRUTAKNA (atacice p t-vymj), a first-in-class BAFF and APRIL inhib itor that could transform treatment of autoimmune d isease • FDA g rante d acce le rate d ap p roval in Ig AN • Phase 3 final analysis re sults sup p ort sBLA sub mission in Q4 2026 APRIL, A p roliferation-ind ucing lig and ; BAFF, B-ce ll activating facto r, also kno wn as B lymp ho cyte stimulato r (BLyS); e GFR, e stimate d g lo me rular filtratio n rate ; Ig AN, immuno g lo b ulin A ne p hro p athy; sBLA, sup p le me ntal Bio lo g ics Lice nse Ap p lication. 3 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Ve ra p ip e line Re search & Discove ry Pre clinical Clinical Marke te d Ig AN TRUTAKNA p MN, FSGS, MCD Phase 2 Potential future autoimmune ind ications Phase 2 MAU868 BK virus Potential future VT-109 autoimmune ind ications Ve ra hold s world wid e , e xclusive rig hts to d e ve lop and comme rcialize TRUTAKNA, VT-109, and MAU868 FSGS, focal se g me ntal g lome ruloscle rosis; MCD, minimal chang e d ise ase ; p MN, p rimary me mb ranous ne p hrop athy. 4 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Manag e me nt team: Succe ssful clinical and comme rcial track re cord Marshall Ford yce, MD Nancy Boman, MD, PhD Rob ert Brenner, MD Lauren Frenz, MBA Found e r and CEO Chie f Re g ulatory O ffice r Chie f Me d ical O ffice r Chie f Busine ss O ffice r Matt Ske lton Sean Grant, MBA David Johnson, MBA Jane Wrig ht-Mitche ll Chie f Financial O ffice r Chie f O p e rating O ffice r Chie f Comme rcial O ffice r Chie f Le g al O ffice r 5 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Strong financial p osition ~72.1M ~$499M Shares outstand ing Cash, cash e q uivale nts, (as of 7.29.26) and marketab le securities (as of 6.30.26) Ad d itional $425M non-d ilutive cap ital availab le throug h O xford Facility, sub je ct to satisfaction of ce rtain cond itions 6 © 2026 Vera Therapeutics, Inc. Corporate Presentation

B ce ll mod ulation via d ual BAFF and APRIL inhib ition re p re se nts a p ote ntial p arad ig m shift in how p atie nts with autoimmunity may b e treate d Autoimmune d isease • Autoantigens and autoantib od ies med iate Autoantib od ie s b ind to autoantig e ns autoimmune d isease BAFF • B ce lls are source of autoantib od ie s → B ce ll targ et cell of interest for therap eutic intervention • B ce lls fue le d b y two cytokine s, BAFF and APRIL APRIL 1 TACI t ~ 40 d ays 1/2 TRUTAKNA recep tor BAFF Kd • Rationally d esig ned therap eutic of mod ern b iotechnolog y 1 106 p M Fc d omain of Ig G1 • Native TACI-Fc fusion p rote in: solub le re ce p tor b ind s BAFF and APRIL with APRIL Kd p icomolar b ind ing affinity 1 33 p M • Offers the p otential for p recision mod ulation of B cells and autoantib od ies Fc, frag me nt crystallizab le ; Ig G1, immunog lob ulin G1; Kd , d isso ciatio n co nstant; TACI, transme mb rane activato r and calcium-m o d ulato r and cyclo p hilin lig and . 1. TRUTAKNA [Pre scrib ing Information]. Brisb ane , CA: Ve ra The rap e utics, Inc; July 2026 . 7 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Ig AN: Most common p rimary g lome rular d isease world wid e 1 Estimate d world wid e incid e nce of 2.5/100,000 cases p er year in ad ults Pre d ominantly d iag nose d in young ad ults, with most p atie nts p re se nting with 2-5 d e monstrab le CKD at time of d iag nosis At least 50% of p atients p rog ress to kid ney failure or d eath within 10 to 20 years 50 % 2,3 of d iag nosis 2025 KDIGO Guid e line re comme nd s treatme nt g oal of red ucing rate of loss of <1 mL/min/y 6 kid ney function to the p hysiolog ical state (<1 mL/min/year for most ad ults) A d isease -modifying the rapy cap ab le of stab ilizing kid ney function is an unmet need CKD, chro nic kid ne y d ise ase . 1. McGrog an A, e t al. Ne p hrol Dial Transp lant 2011; 2. Kwon CS, e t al. J He alth Econ O utcome s Re s 2021; 3. Pitche r D, e t al. Clin J Am Soc Nep hrol 2023; 4. Jarrick S, et al. J Am Soc Nep hrol 2019; 5. Caster DJ, et al. Kid ney Int Rep . 2023; 6. KDIGO IgAN and Ig AV Work Group . Kid ne y Int. 2025. 8 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Inhib ition of immune comp lex formation in Ig AN may offe r the p ote ntial to avoid e nd -stag e kid ney d isease d uring a p atient’s lifetime 80 71 60 59 ESKD 5-year mortality 40 comp arab le to cance r 35 20 8 0 Lung ESKD Colorectal Breast Cancer Cancer Cancer ESKD, end stag e kid ney d isease. 1. US CDC Cance r Statistics b ase d on cance rs d iag nose d from 2015 to 2021 and fo llo w-up of p atie nts throug h De c 31, 2021; 2. Thurlow JS, et al. Am J Nep hrol 2021 (d ata for ESKD resulting from all kid ney d isease). 9 © 2026 Vera Therapeutics, Inc. Corporate Presentation 1,2 5-Ye ar % Mortality in US

Ig AN is a d isease of B ce ll orig in with kid ne y p atholog y B ce ll activation Formation of circulating immune comp le xe s Immune comp le x d e p osition le ad ing to g lome rulone p hritis and kid ne y d amag e BAFF TACI Autoantig e n (Gd -Ig A1) B ce ll Autoantib od y (anti-Gd -Ig A1) Glomerulus APRIL 1 2 3 4 5 BAFF and APRIL Activated B cells prod uce …forming …which d eposit in the …and progressive activate B cells via autoantigen (Gd-IgA1) and immune mesangium, resulting in kid ney injury with the TACI receptor autoantibodies (anti-Gd-IgA1)… complexes… glomerular inflammation hematuria, proteinuria, (nephritis)… and eGFR d ecline e GFR, e stimate d g lome rular filtration rate ; Gd -IgA1, galactose-d e ficie nt im m uno g lo b ulin A1. 10 © 2026 Vera Therapeutics, Inc. Corporate Presentation

TRUTAKNA: Rationally d e sig ne d fusion p rote in conce ive d in the e ra of mod e rn b iote chnolog y B ce ll activation Formation of circulating immune comp le xe s Immune comp le x d e p osition le ad ing to g lome rulone p hritis and kid ne y d amag e BAFF TACI Autoantig e n (Gd -Ig A1) B ce ll Autoantib od y (anti-Gd -Ig A1) Glomerulus APRIL TACI TRUTAKNA recep tor • Rationally d e sig ne d native human TACI-Fc fusion p rote in Fc d omain • Solub le recep tor b ind s key cytokines BAFF and APRIL with p icomolar b ind ing affinity of Ig G1 • Offers the p otential for p recision mod ulation of B cells and autoantib od ies 11 © 2026 Vera Therapeutics, Inc. Corporate Presentation

A therap y that comp rehensively ad d resses KDIGO treatment g oals would ... Red uce immune comp lexes (Gd -Ig A1) Resolve inflammation (hematuria) Red uce p roteinuria Stab ilize eGFR Fig ure s are illustrative o nly. 12 © 2026 Vera Therapeutics, Inc. Corporate Presentation

O RIGIN Phase 2b long -te rm re sults consiste nt with d isease mod ification Red uction in Gd -Ig A1 Resolution of hematuria 0 0 -15 -20 -30 -40 -45 -60 -75 % -60 -80 -66 % -75 -100 0 12 24 36 48 60 72 96 0 12 24 36 48 60 72 84 96 Week from First Active Dose We e k from First Active Dose n= 111 108 78 107 79 29 77 74 n= 63 62 60 60 61 61 43 41 40 Red uction in p roteinuria Stab ilization of eGFR 0 10 5 -20 Slop e 0 -0.6 -40 mL/min/year -5 2 Annualize d e GFR slo p e o f -0.6 mL/min/1.73m p er year -52 % Me an e GFR chang e from b ase line -60 -10 0 12 24 36 48 60 72 84 96 0 12 24 36 48 60 72 84 96 We e k from First Active Dose We e k from First Active Dose n= 113 110 107 109 109 108 78 74 75 n=112 110 108 108 109 108 78 76 75 Data includ e s all p articip ants re ce iving any active d ose at any time p oint, with b ase line (BL, we e k 0) d e fine d as last availab le measurement p rior to first active d ose. CI, confid ence interval; UPCR, urine p rotein creatinine ratio. Barratt J, et al. J Am Soc Nep hrol 2025. 13 © 2026 Vera Therapeutics, Inc. Corporate Presentation Mean ± SE % Chang e from BL Mean ± SE % Change from BL in UPCR in Gd-IgA1 Mean ± SE Change from BL in Chang e fro m BL 2 eGFR, mL/min/1.73m in % Particip ants (95% CI)

Phase 3 trial d e sig n Multinational, rand omize d , p lace b o-controlle d trial of TRUTAKNA, se lf-ad ministe re d at home via we e kly 1-mL SC inje ction Doub le -Blind Tre atme nt O p en-Lab el Extension Place b o TRUTAKNA 150 mg SC Q W TRUTAKNA 150 mg SC Q W Week 0 36 52 104 156 1° End point met Final analysis: 2° End points met Ke y Inclusion Crite ria End p oints • Patie nts ≥18 ye ars old with b iop sy-p rove n Ig AN and hig h risk of • Primary: UPCR-24h % change at 36 weeks d isease progression • Key second ary: eGFR change from b aseline at 52 weeks • Stab le and op timize d RASi for ≥12 we e ks, use of SGLT2i allowe d • Se cond ary: • UPCR-24h ≥1.0 g /g or UP ≥1.0 g p e r 24h – eGFR slope through 104 weeks 2 • e GFR ≥30 mL/min/1.73m – UPCR chang e at 52 we e ks • Blood p re ssure ≤150/90 mmHg – Hematuria resolution at 52 weeks – Time to comp osite kid ne y d isease p rog re ssion e nd p oint • Safe ty RASi, re nin-ang io te nsin syste m inhib ito r; SGLT2i, so d ium-g lucose co transp o rte r-2 inhib ito r. 14 © 2026 Vera Therapeutics, Inc. Corporate Presentation

O RIGIN 3 inte rim analysis se t p articip ant d isp osition 750 scre e ne d 319 faile d scre e ning 431 rand omize d 428 rand omize d and tre ate d Full analysis se t and 214 TRUTAKNA 214 p lace b o safe ty analysis se t 106 TRUTAKNA Inte rim analysis se t 97 p lace b o 7 d iscontinue d tre atme nt 13 d iscontinue d tre atme nt 2 5 p atie nt withd rawal 7 ad verse event 1 1 ad verse event 3 p atie nt withd rawal 1 p rotocol d e viation 2 p hysician d e cision 1 p rotocol d e viation 99 (93.4%) Tre atme nt ong oing 84 (86.6%) 1. Rash. 2. Prote inuria, chronic kid ne y d ise ase , Ig AN, p arop hthalmia, p ne umo nia, p ye lo ne p hritis, oste one cro sis, caro tid arte ry ane urysm. 15 © 2026 Vera Therapeutics, Inc. Corporate Presentation Inte rim analysis se t

O RIGIN 3 and O RIGIN 2b d e mog rap hics and b ase line characte ristics ORIGIN 3 Inte rim Analysis Se t ORIGIN 2b TRUTAKNA Place b o Total Total n=106 n=97 n=203 N=116 Ag e, med ian (rang e), years 40 (18, 72) 39 (19, 70) 40 (18, 72) 37 (18, 67) Male sex, n (%) 57 (54) 58 (60) 115 (57) 69 (59) Race , n (%) White 46 (43) 42 (43) 88 (43) 62 (53) Asian 59 (56) 52 (54) 111 (55) 51 (44) Black or African Ame rican 0 1 (1) 1 (0.5) 0 Native Hawaiian or othe r Pacific Island e r 0 1 (1) 1 (0.5) 1 (1) O the r/not re p orte d 1 (1) 1 (1) 2 (1) 2 (2) Hisp anic/Latino e thnicity, n (%) 14 (13) 6 (6) 20 (10) 4 (3) 2 e GFR, me an ± SD, mL/min/1.73 m 65 ± 28 65 ± 29 65 ± 28 63 ± 27 UPCR b y 24h urine , me an ± SD, g /g 1.7 ± 0.9 1.8 ± 1.2 1.7 ± 1.0 1.6 ± 0.9 Time since b iop sy, me an ± SD, ye ars 2.5 ± 2.6 2.5 ± 2.4 2.5 ± 2.5 2.8 ± 2.8 SGLT2i use , n (%) 59 (56) 49 (51) 108 (53) 16 (14) 16 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Primary e nd p oint: UPCR re d uction Δ 42% 95% CI 29, 52 p <0.0001 10 10 0 0 -10 -10 -20 -20 -7% -30 -30 95% CI -19, 8 -40 -40 -50 -50 -46% -60 -60 95% CI -53, -38 0 12 24 36 n= Week Placeb o 97 96 97 95 TRUTAKNA Placeb o TRUTAKNA 106 104 104 103 n=103 n=95 Interim Analysis Set (IAS) includ ed the first 203 rand omized p articip ants who received ≥1 d ose of trial d rug . Chang e from b as eline in natural-lo g transfo rme d UPCR at We e k 36 was analyze d using a mixe d -effects mod el with rep eated measurement (MMRM), includ ing fixed effects for treatment g roup , visit as a categ orical variab le, treatment-by-visit inte ractio n, b ase line natural-log transforme d UPCR, b ase line e GFR cate g ory, SGLT2i use at b ase line , and re g ion, with p articip ant as a rand om e ffe ct. log -transformed chang e from b aseline in UPCR was estimated with use of least-sq uare s me ans. To facilitate inte rp re tation of the re sult, the le ast-sq uare s me ans e stimate was b ack-e xp o ne ntiate d to o b tain the e q uivale nt g e ome tric me an p e rce ntag e chang e . MMRM analysis includ e d d oub le-blind pe riod data up to We e k 36, re g ardle ss of tre atme nt discontinuation or initiation of re scue tre atme nt for Ig AN or p rohib ite d the rap y; missing value s afte r stud y withd rawal we re imp ute d with jump to re fe re nce (p lace b o) ap p roach for 100 time s. The Rub in rule was use d to comb ine re sults estimate d from e ach of 100 imp utation d atase ts b y MMRM analysis. 17 © 2026 Vera Therapeutics, Inc. Corporate Presentation Mean (95% CI) % Chang e from Baseline

UPCR efficacy consistent across prespecified subgroups n (%) Mean UPCR % Chang e at Week 36 Me an UPCR % Re d uction Favors Placebo Favors TRUTAKNA vs Place b o (95% CI) TRUTAKNA Place b o TRUTAKNA Place b o O ve rall 106 97 -46% -7% 42% (29, 52) <40 48 (45) 49 (51) -44% +0.5% 45% (23, 60) Ag e, years ≥40 58 (55) 48 (50) -46% -14% 38% (21, 51) Male 57 (54) 58 (60) -41% -9% 35% (14, 51) Se x Fe male 49 (46) 39 (40) -51% -2% 50% (34, 62) Asia 50 (47) 48 (50) -50% -14% 42% (18, 58) Re g ion O the r 56 (53) 49 (51) -42% +1% 43% (29, 55) White 46 (43) 42 (43) -42% +0.1% 42% (26, 55) Non-white -48% -11% 60 (57) 55 (57) 42% (22, 57) Race Asian 59 (56) 52 (54) -47% -12% 40% (19, 56) Non-Asian 47 (44) 45 (46) -44% +0.6% 44% (29, 56) <1.5 53 (50) 47 (49) -44% +3% 46% (28, 59) ≥1.5 53 (50) 50 (52) -48% -13% 41% (21, 55) BL UPCR, g /g <1.0 25 (24) 29 (30) -42% +5% 45% (17, 64) ≥1.0 81 (76) 68 (70) -48% -10% 42% (27, 54) <60 50 (47) 52 (54) -35% -1% 34% (13, 51) ≥60 56 (53) 45 (46) -53% -14% 45% (27, 59) BL e GFR, 2 mL/min/1.73m <45 33 (31) 34 (35) -38% +3% 40% (15, 58) ≥45 73 (69) 63 (65) -49% -11% 43% (26, 55) Ye s 59 (56) 49 (51) -48% -7% 44% (26, 58) SGLT2i use at BL No -43% -6% 47 (44) 48 (50) 39% (19, 54) Sub g roup analyse s we re cond ucte d using the same imp ute d d ata se ts and the same MMRM mod e l as for the -60 -40 -20 0 20 40 60 p rimary analysis for e ach sub g roup cate g ory, se p arate ly. If the sub g roup was one of the covariate s in the mod e l, the covariate was removed from the mod el statement when the mod el was p erformed for the p articular sub g roup . Mean UPCR % Reduction vs Placebo at Week 36 (95% CI) 18 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Gd -Ig A1 re d uction and he maturia re solution Gd -Ig A1 Re d uction He maturia Re solution 0 0 -3% -20 -21% -15 -40 -30 O d d s ratio 19.1 Δ 67% p <0.0001 p<0.0001 -60 -45 -80 -60 -81% -68% -75 -100 0 4 12 24 36 0 2 4 12 24 36 Week Week n= Placebo 97 93 93 94 95 58 58 58 58 58 58 TRUTAKNA 104 103 96 100 101 64 61 64 64 64 63 Analysis includ e d all d ata up to We e k 36 analyze d acco rd ing to tre atme nt p o licy strate g y. Missing d ata we re hand le d imp licitly b y statistical m o d e l. No m inal p -values are p resented . 1. Chang e from b ase line in natural log -transfo rme d Gd -Ig A1 was analyze d using MMRM similar to that for the p rimary e nd p o int. 2. Percentag es rep resent chang e from b aseline in numb er of p articip ants with hematuria (urine d ip stick b lood ≥1+) at e ach visit d ivid e d b y numb e r of p articip ants with b ase line he maturia shown on the lo we r axis; re solutio n d e fine d as urine d ip stick b lood of trace or ne g ative . O d d s ratio is calculate d from a log istic re g re ssion mod e l ad juste d for covariate s. 19 © 2026 Vera Therapeutics, Inc. Corporate Presentation 1 Mean (95% CI) % Change from Baseline Change from Baseline in % 2 Patie nts with He maturia (95% CI)

TRUTAKNA was g e ne rally we ll tole rate d in O RIGIN 3 inte rim analysis TRUTAKNA Place b o Particip ants, % n=214 n=214 Most common ad ve rse e ve nts (≥5%) • Most ad verse events were mild or mod erate in severity and resolved without treatment Infe ctions 32 28 interrup tion or d iscontinuation Up p e r re sp iratory tract infe ction 12 9 • Rate of serious ad verse events was lower in the Local ad ministration re actions 30 5 atacicept group compared with placeb o Inje ction site re action 19 2 • No clinically re le vant hyp og ammag lob uline mia Injection site erythema 6 1 1 Serious ad verse events 0.5 5 • No clinically sig nificant effect of anti-d rug 2 antib od ie s on PK, PD, safe ty or e fficacy Ad ve rse e ve nts le ad ing to d rug d iscontinuation 1 4 Serious or severe infections 0 1 • No d eaths occurred O p p ortunistic infe ctions 0 0 Hyp e rse nsitivity re actions 4 7 Ad verse events le ad ing to d e ath 0 0 Analysis of safe ty p op ulation (all p articip ants rand omize d and tre ate d ) as of inte rim d ata cut on 15-May-2025. 1. TRUTAKNA: cho le cystitis, d e te rmine d b y site inve stig ator to b e unre late d to tre atme nt; Place b o (n=1 e ach): g astroe nte ritis, lowe r re sp iratory tract infe ction, p ne umonia, p ye lone p hritis, Ig A ne p hrop athy, re nal imp airme nt, acute myocard ial infarctio n, transp lant re je ctio n, hyp o natre mia, o ste o ne cro sis, o varian e p ithe lial cance r, caro tid arte ry ane urysm, hyp e rte nsion, acute cholecystitis. 1 p laceb o serious ad verse event was d eemed related to stud y d rug . 2. Discontinuations in the 2 TRUTAKNA p articip ants we re d ue to e cze ma and e rythe ma. 20 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Ve ra The rap e utics Announce s Alig nme nt with U.S. FDA on Earlie r O RIGIN Phase 3 Analysis to Sup p ort Potential Full Ap p roval for Atacicep t in Ad ults with Ig A Nep hrop athy • Re vise d O RIGIN 3 e GFR analysis now p lanne d for Q3 2026, p ulle d forward from 2027 • Pe nd ing p ositive e GFR analysis, p lans to sub mit a sup p le me ntal Biolog ics Lice nse Ap p lication (sBLA) in Q4 2026, with p ote ntial full ap p roval in 2027 BRISBANE, Calif., June 02, 2026 (GLO BE NEWSWIRE) -- Ve ra The rap e utics, Inc. (Nasd aq : VERA), a b iote chnolog y comp any focused on d evelop ing and commercializing transformative treatments for p atients with serious immunolog ical d isease s, tod ay announce d it has alig ne d with the U.S. Food and Drug Ad ministration (FDA) on a re vise d , earlie r O RIGIN 3 e GFR analysis p lan to sup p ort full ap p roval for atacice p t in ad ults with Ig AN. The e GFR results are now exp ected in the third q uarter of 2026. Pend ing these results, Vera Therap eutics p lans to sub mit an sBLA for full ap p roval in the fourth q uarter of 2026. Alig nme nt with the FDA on a re vise d e GFR analysis p lan follows a re ce nt workshop hoste d b y the National Kid ne y Found ation which includ e d clinicians, re searche rs, re g ulators, and p atie nt ad vocate s. In ad d ition, the alig nme nt with the FDA has b een sup p orted b y the eGFR results from the ORIGIN Phase 2b trial of atacicep t in Ig AN. 21 © 2026 Vera Therapeutics, Inc. Corporate Presentation

O RIGIN 3 final efficacy analysis: d emog rap hics and b aseline characteristics TRUTAKNA Place b o Total n=214 n=214 n=428 Ag e, med ian (rang e), years 41 (18, 74) 41 (18, 70) 41 (18, 74) Male sex, n (%) 122 (57) 132 (62) 254 (59) Race , n (%) Asian 117 (55) 114 (53) 231 (54) White 94 (44) 95 (44) 189 (44) O the r 3 (1) 5 (2) 8 (2) 2 e GFR, mean ± SD, mL/min/1.73 m 65 ± 27 63 ± 27 64 ± 27 UPCR b y 24h urine , mean ± SD, g /g 1.6 ± 0.9 1.6 ± 1.0 1.6 ± 1.0 Time since b iop sy, mean ± SD, years 2.6 ± 2.6 2.3 ± 2.4 2.4 ± 2.5 SGLT2i use , n (%) 134 (63) 129 (60) 263 (61) 22 © 2026 Vera Therapeutics, Inc. Corporate Presentation

TRUTAKNA stabilized eGFR compared to placebo through 104 weeks 2 Mean change Annualized from baseline eGFR slope 0 1 2 at 52 weeks at 104 weeks -2 Placebo- Δ 5.6 Δ 5.0 adjusted (3.7, 7.5) (3.6, 6.5) -4 difference p <0.0001 p <0.0001 -6 TRUTAKNA -0.1 -0.6 -8 (-1.4, 1.2) (-1.6, 0.4) -10 Place b o -5.7 -5.6 (-7.0, -4.4) (-6.6, -4.6) -12 -14 -16 0 4 12 24 36 48 52 60 72 84 96 104 Week n= TRUTAKNA 214 209 209 208 205 197 202 165 159 102 72 50 Placeb o 214 209 210 208 203 195 193 155 136 81 60 37 1. Change from baseline in eGFR was analyzed using a mixed model for repeated measures (MMRM). 2. Annualized eGFR slope was analyzed using a mixed model with random intercept and random slope. 23 © 2026 Vera Therapeutics, Inc. Corporate Presentation Mean (95% CI) eGFR chang e from b aseline, 2 mL/min/1.73m

TRUTAKNA achieved unp reced ented kid ney p rotection with a 76% risk re d uction in the comp osite kid ney end p oint Kid ney d isease p rog ression events • The hazard ratio for comp osite kid ne y d isease p rog re ssion was 0.24 (95% CI 0.12, 0.48; 40 38 p <0.0001), re sulting in a 76% risk red uction 18% throug h 104 we e ks 30 • A comp osite kid ne y d ise ase p rog re ssion e ve nt was d e fine d as the first occurre nce of ≥1 of the following : 20 – Death 11 – Kid ne y transp lant 8 10 5% – Chronic d ialysis ≥30 d ays 4% 2 0 – e GFR <15 mL/min/1.73m , sustaine d for ≥30 d ays 0 Sustained ≥30% eGFR Dialysis, transp lant or – ≥30% e GFR d e cline sustaine d for ≥30 d ays d e cline d e ath TRUTAKNA Place b o Hazard ratio, 95% CI, and the like lihood ratio te st p -value are calculate d b ase d o n Co x p ro p o rtio nal hazard mo d e l. 24 © 2026 Vera Therapeutics, Inc. Corporate Presentation Particip ants, n

TRUTAKNA was well tolerated with a favorab le safety p rofile, and g enerally comparable to place bo TRUTAKNA Place b o Particip ants, n (%) n=214 n=214 • Most ad verse events were mild or mod erate in Ad verse events 160 (75) 167 (78) se ve rity and re solve d without tre atme nt 1 inte rrup tion or d iscontinuation Serious ad verse events 15 (7) 33 (15) Ad ve rse e ve nts le ad ing to d rug d iscontinuation 4 (2) 22 (10) • Inje ction site reactions we re mild or mod e rate Ad ve rse e ve nts of infe ctions and infe stations 110 (51) 112 (52) • Rate of serious ad verse events was lower in the TRUTAKNA g roup comp are d with p lace b o Se rious or se ve re infe ctions and infe stations 6 (3) 8 (4) O p p ortunistic infe ctions 0 0 • No clinically re le vant hyp og ammag lob uline mia 2 Stud y d rug related ad verse events 75 (35) 38 (18) • No op p ortunistic infe ctions 3 Ad ve rse e ve nts associate d with inje ction site re actions 54 (25) 16 (7) • No d e aths occurre d in the TRUTAKNA g roup Hyp e rse nsitivity re actions 21 (10) 23 (11) Ad verse events le ad ing to d e ath 0 1 (0.5) • No clinically sig nificant effect of anti-d rug antib od ies on PK, PD, safety or efficacy Analysis of safe ty p op ulation (all p articip ants rand omize d and tre ate d ) as of d ata cut on 10-Jun-2026. 1. In the p lace b o p atie nts with se rious ad ve rse e ve nts, 7 had e ve nts characte rize d as kid ne y and urinary d iso rd e rs. Ad d itional lab oratory-related events includ ed d ecreased eGFR in 2 p atients and increased b lood creatinine in 1. There were no kid ne y/urinary o r kid ne y-related lab oratory serious ad verse events in the atacicep t g roup . 2. Majority of stud y d rug re late d ad ve rse e ve nts we re mild to mod e rate inje ction site re actions that d id not le ad to d iscontinuation. 3. Injectio n site reactio ns amo ng atacicep t recip ients were larg ely characterized b y injectio n site erythema, hemato ma, and p ruritis. 25 © 2026 Vera Therapeutics, Inc. Corporate Presentation

O RIGIN 3 final e fficacy analysis summary • TRUTAKNA has d e monstrate d that up stream inhib ition of BAFF and APRIL achie ve s re sults that re fle ct the p ote ntial for comp re he nsive d ise ase mod ification in Ig AN • Me t all p re d e fine d e nd p oints, includ ing unp re ce d e nte d p lace b o-ad juste d e GFR and comp osite kid ne y p rog re ssion b e ne fits 2 – Place b o-ad juste d d iffe re nce in mean e GFR chang e from b ase line of 5.6 mL/min/1.73m at 52 we e ks 2 – Place b o-ad juste d d iffe re nce of 5.0 mL/min/1.73m /ye ar in annualize d e GFR slop e throug h 104 we e ks – 76% risk re d uction in the comp osite kid ne y p rog re ssion e nd p oint – Statistically sig nificant re d uctions in UPCR, Gd -Ig A1 and he maturia • TRUTAKNA was we ll tole rate d with a favorab le safe ty p rofile , and g e ne rally comp arab le to p lace b o The se re sults sup p ort the rationale for the alig nme nt b e twe e n FDA and Ve ra to p ull forward the timing of the final O RIGIN 3 e fficacy analysis, offe ring p atie nts on p lace b o an earlie r op p ortunity to transition to op e n-lab e l TRUTAKNA for the re maind e r of the trial 26 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Estimated Ig AN ep id emiolog y in 2032 1 US Ig AN Prevalence: ~ 0.04% of US Pop ulation (360.5M) + ~40K Low Risk ~160K 2 (~ 24% of p atie nts) + ~30K Mod erate Risk 2 (~ 20% of p atie nts) ~90K Hig h Risk 2 (~ 56% of p atie nts) Phase 3 p op ulation Phase 2 stud y ong oing BAFF & APRIL inhib ition Patie nt counts round e d to ne are st 1,000. 1. Cle arvie w He althcare Partne rs Analysis 2021; 2. Pitche r D, e t al. Clin J Am Soc Ne p hrol 2023. Low risk assume d to b e 0–<0.44 g /g UPCR, mod erate risk assumed to b e 0.44–0.88 g /g , hig h risk assume d to b e >0.88 g /g ; p e rce ntag e of p atie nts pe r pro te inuria cate g o ry in study po pulatio n 1 applie d to e stimate d US Ig AN pre vale nce . 27 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Clinical p ractice g uid elines encourag e p roactive treatment of Ig AN to minimize nep hron loss 1 TRUTAKNA may hit the mark Tre atm e nt g uid e line s Biop sy and treatme nt initiation thre shold of ≥0.5g /d ay p rote inuriaü Pote ntially d ise ase -mod ifying , d ual-inhib ition MoA 2 • Pre ve ntion of Ig A-IC formationü 68% Gd -Ig A1 re d uction 2 • Anti-inflammation/anti-fib rosisü 81% he maturia re solution 2 • <0.3— <0.5 g /d p rote inuria ü 46% UPCR re d uction • <1 mL/min/ye ar e GFR lossü -0.6 mL/min/ye ar e GFR slop e 2 • Manag e me nt of g e ne ric re sp onse s ü Ge ne rally we ll tole rate d to Ig AN-ind uce d ne p hron loss IC, immune comp lex. 1. Kid ne y Dise ase : Imp ro ving Glob al O utcome s (KDIGO ) Ig AN and Ig AV Wo rk Group . KDIGO 2025 Clinical Practice Guid e line for the Manag e me nt of Ig AN and Ig AV. Kid ne y Int. 2025;108(4S):S1–S71. 2. Interim results from Lafayette R, et al. N Engl J Med 2025. 28 © 2026 Vera Therapeutics, Inc. Corporate Presentation

Ig AN marke t and TRUTAKNA have many hallmarks of an attractive comme rcial op p ortunity Ig AN Marke t TRUTAKNA • We b e lie ve the ne p hrolog y marke t is rip e for • Pote ntially d iffe re ntiating p rod uct attrib ute s d isrup tion d ue to limite d ad op tion of • Phase 2b e GFR d ata hig hly value d with ap p rove d the rap ie s e nthusiastic sup p ort from the rap e utic exp e rts 3 • Larg e marke t with unme t ne e d and insig hts cap ture d at advisory boards 1 • Growing IgAN population • Exp e rie nce d comme rcial team active ly p romoting in the fie ld 2 • Favorab le p aye r mix • Exciting life cycle op p ortunitie s 1. ClearView He althcare Partne rs Analysis; 2. Bluep ath So lutio ns re se arch co nd ucte d in Q 4 2024; 3. Sp herix Re altime Dynamix US Ig AN ind e p e nd e nt surve y cond ucte d in Q4 2024 and ad visory b oard s cond ucte d b y Ve ra The rap e utics. 29 © 2026 Vera Therapeutics, Inc. Corporate Presentation

1 Pote ntial $10B+ U.S. marke t op p ortunity in Ig AN and p ip e line autoimmune d ise ase s LCM for BAFF and APRIL inhib ition 1 US Pre vale nce Ig AN/Ig AVN Sjög re n’s Ne p hrolog y Non-Ne p hrolog y p MN ~500K ~700K g MG FSGS SLE MCD ITP AAV SSc LN 1. Vera Therap eutics corp orate estimates for p eak year market op p ortunity and p revalence b ased on ClearView He althcare Partne rs Analysis 2025. AAV, anti-ne utro p hil cyto p lasm ic antib o d y-associate d vasculitis; FSGS, fo cal se g me ntal g lo me rulo scle ro sis; g MG, g e ne ralize d m yasthe nia g ravis; Ig AVN, IgA vasculitis nep hritis; ITP, immune thromb ocytop enia; LCM, lifecycle management; LN, lup us ne p hritis; MCD, minimal chang e d ise ase ; p MN, p rimary me mb ranous ne p hrop athy; SLE, syste mic lup us e rythe mato sus; SSc, syste mic scle ro sis. 30 © 2026 Vera Therapeutics, Inc. Corporate Presentation

TRUTAKNA p roje cte d catalysts Catalyst 2026 2027 2028 US launch Ig AN Phase 3 final e fficacy analysis 1 Proje cte d full ap p roval Ig AN Clinical re sults Ig AN, p MN, Clinical re sults FSGS, MCD Ve ra hold s world wid e , e xclusive rig hts to d e ve lop and comme rcialize TRUTAKNA 1. Sub je ct to U.S. FDA re vie w of full clinical d atase t and ap p roval. 31 © 2026 Vera Therapeutics, Inc. Corporate Presentation